Washington, DC 20006-5349
HELPLINE
In this episode of Meso TV, our Director of Patient Services, Julie, talks with Dr. Timothy Yap from MD Anderson Cancer Center about the VT3989 clinical trial for mesothelioma. He explains what this new treatment is, how it works, and what it could mean for patients.VT3989 is a YAP/TEAD inhibitor,…
On this episode of MesoTV, our Patient Services Director, Julie White, sits down with Melissa Culligan, PhD, RN. Melissa is the Director of Thoracic Surgery Research at Temple University Hospital and the Co-Director of the Temple Health Mesothelioma and Pleural Disease Program. She goes through the details of thoracic surgery…
Andreas Rimner, MD, Memorial Sloan Kettering Cancer Center, joins us for a conversation about radiation oncology and currently available clinical trials. He discussed various ways…
Dr. Melissa Johnson of the Sarah Cannon Cancer Center in Nashville, TN talks to us about a multi-center clinical trial utilizing engineered t-cell therapy similar…
Intro Dr. Patrick Forde, MD, is leading the charge in a new clinical trial investigating the effectiveness of immunotherapy in patients who are surgical candidates.…
When it comes to dealing with a mesothelioma diagnosis and its treatment, patients and their physicians are faced with many decisions. Recently, the Mesothelioma Applied…
This MesoTV panel of four mesothelioma patients and one caregiver discuss survivors’ guilt and other issues affecting mesothelioma survivors. Chris DeSantis Heather Von St James…
Marjorie G. Zauderer, MD, discusses a currently enrolling Phase 1 clinical trial for mesothelioma patients. This CAR-T cell therapy trial targets mesothelin, a protein heavily…
Kanwal Raghav, MD, discusses the results of a Phase 2 trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma. Dr.…
Bonnie Anderson is a 19-year mesothelioma survivor. She discusses her peritoneal mesothelioma diagnosis in 2002, her history with multiple cancers, and her family’s advocacy efforts…
